Abate Kristin 4
4 · Karyopharm Therapeutics Inc. · Filed Jan 29, 2026
Research Summary
AI-generated summary of this filing
Karyopharm (KPTI) CAO Kristin Abate Receives Award and Sells Shares
What Happened Kristin Abate, Chief Accounting Officer of Karyopharm Therapeutics (KPTI), had 92 performance-based restricted stock units (PSUs) certified as earned and vested on Jan 27, 2026 and received 92 underlying shares (acquired at $0.00). On Jan 28, 2026 she sold 50 of those shares in a broker-assisted open-market transaction at $7.03 per share, generating $352 — a sale to satisfy tax withholding on the vested PSUs, not an active trading decision.
Key Details
- Transaction dates: PSUs certified and vested/issued on 2026-01-27; sale executed on 2026-01-28; Form 4 filed 2026-01-29.
- Acquisition: 92 shares as the result of earned PSUs, price $0.00 (footnote F1).
- Sale: 50 shares disposed at $7.03 each, total proceeds $352 (footnote F2).
- Reason for sale: Broker-assisted sale pursuant to a durable automatic sale instruction plan to cover withholding taxes — not a discretionary trade by the reporting person (F2).
- Shares owned after transaction: Not specified in this filing.
- Filing timeliness: Form 4 was filed two days after the vesting date (appears timely under Form 4 rules).
Context The 92 shares came from PSUs granted in February 2023 that were performance-based; the Compensation Committee certified achievement of milestones (revenue and TSR) on Jan 27, 2026, and the earned PSUs vested that same day (F1). The small broker-assisted sale (50 shares, $352) was solely to cover tax withholding and is routine; it does not necessarily indicate a change in the insider’s view of the company.
Insider Transaction Report
- Award
Common Stock
[F1]2026-01-27+92→ 22,672 total - Sale
Common Stock
[F2]2026-01-28$7.03/sh−50$352→ 22,622 total
Footnotes (2)
- [F1]Represents the number of shares of the issuer's common stock underlying performance-based restricted stock units ("PSUs") granted in February 2023 that have been earned based on the level of achievement of the revenue and total shareholder return milestones as certified by the issuer's Compensation Committee on January 27, 2026. Each earned PSU represents the contingent right to receive one share of the issuer's common stock upon vesting. The earned PSUs vested on January 27, 2026.
- [F2]This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on May 27, 2021, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of PSUs. The sale does not represent a discretionary trade by the reporting person.